ライフサイエンスコーパス: vaginal infection

1 cine for efficacy in a BALB/c mouse model of vaginal infection.

2 rm birth rates in a mouse model of ascending vaginal infection.

3 se rendered recipients more resistant to HSV vaginal infection.

4 protect against disseminated candidiasis and vaginal infection.

5 imental disseminated candidiasis and Candida vaginal infection.

6 l concentration of oxytetracycline following vaginal infection.

7 ibodies, can help the host to resist Candida vaginal infection.

8 possible source of initial cell contact for vaginal infection.

9 cacy of a novel regimen to prevent recurrent vaginal infections.

10 in prevention of diseases that develop from vaginal infections.

11 ually transmitted infections and symptomatic vaginal infections.

12 ion during primary and secondary C. albicans vaginal infections.

13 en observed in experimental Candida albicans vaginal infections.

14 c factors controlling the immune response to vaginal infections.

15 rtain intestinal and, possibly, treatment of vaginal infections.

16 y lactobacilli have decreased acquisition of vaginal infections.

17 ral treatment administered monthly to reduce vaginal infections among Kenyan women at risk for HIV-1

18 significantly reduced the clinical signs of vaginal infection and effectively decreased animal morta

19 11,392 women who enrolled in the multicenter Vaginal Infections and Prematurity Study (1984-1989) at

20 s play a role in limiting and clearing HSV-2 vaginal infections and that they are, in association wit

21 ch higher for paint applications, influenza, vaginal infections, and ultrasound (reaching, e.g., 4-6)

22 innate resistance by neutrophils against the vaginal infection appear negligible, significant in vitr

23 nt experimental rodent models of C. albicans vaginal infection are used for many applications, the ro

24 Vaginal infections are common and have been associated w

25 Vaginal infections are common, frequently recur, and may

26 w these marked differences in the biology of vaginal infection between these otherwise genetically si

27 Ab B6.1 also protected against C. tropicalis vaginal infection, but MAb B6 did not.

28 tions were significantly less susceptible to vaginal infection by C. glabrata, suggesting a potential

29 nt a dominant host defense mechanism against vaginal infections by Candida albicans.

30 uent contact with HSV-specific T cells after vaginal infection compared with epicutaneous infection.

31 or kidney infections (UTIs) and cervical or vaginal infections (CVIs) during pregnancy, as well as o

32 eudoestrus that were given MAb C3.1 prior to vaginal infection developed fewer vaginal Candida CFU th

33 terval (CI) 1.2-4.0), medical treatments for vaginal infection during pregnancy (OR = 2.4, 95% CI 1.2

34 ficantly elevated odds ratios were noted for vaginal infections during pregnancy (odds ratio (OR) = 2

35 d for the ability to protect against Candida vaginal infection, established by intravaginal (i.vg.) i

36 f delivery about pregnancy events, including vaginal infections, genital herpes, urinary tract infect

37 sotype of the MAb modulates the outcome of a vaginal infection in a murine model.

38 der estrogen-treated conditions, resulted in vaginal infection in rhesus, but not pig-tailed, macaque

39 titative analysis in response to C. albicans vaginal infection in the presence of hormones.Our data s

40 egative women 18-45 years old with 1 or more vaginal infections, including bacterial vaginosis (BV),

41 n conclusion, susceptibility to a chlamydial vaginal infection is dependent on the age of the mice, w

42 Women without evidence of vaginal infection may exhibit transient changes in their

43 Using a vaginal infection model in complement-intact guinea pigs

44 However, the subcutaneous group resolved the vaginal infection more slowly, with 60% (6 of 10 mice) o

45 ently, biofilms have also been implicated in vaginal infections, notably bacterial vaginosis (BV) and

46 bitor (NNRTI) MIV-150 in carrageenan reduced vaginal infection of macaques with simian immunodeficien

47 Notably, vaginal infection of pregnant dams during early pregnanc

48 To assess the effect of treatment of vaginal infections on vaginal shedding of cell-free huma

49 of vaginal T cells occurred during a primary vaginal infection or during a secondary vaginal infectio

50 stered dose appears to impact SHIV(SF162P3N) vaginal infection outcome in an unexpected manner.

51 om the United States and Kenya with a recent vaginal infection received intravaginal metronidazole 75

52 ers significantly greater protection against vaginal infection than seen in unvaccinated mice (P < .0

53 iii) the partial protection from a secondary vaginal infection under pseudoestrus conditions.

54 ilar, but not identical, fashions and caused vaginal infection; (vi) different switch phenotypes of t

55 Vaginal infection was also more efficient in P2X7R-defic

56 riodic presumptive treatment (PPT) to reduce vaginal infections, we observed a significant reduction

57 riodic presumptive treatment (PPT) to reduce vaginal infections were analyzed to assess the effect of

58 roup (19 [23%] vs three [4%], p=0.0005), but vaginal infections were less common (one [1%] vs eight [

59 mary vaginal infection or during a secondary vaginal infection where partial protection was observed.

60 Thus humanized mouse models of HIV vaginal infection will allow the study of the mechanisms

61 ct a substantial proportion of macaques from vaginal infection with a CCR5-using virus (SHIV-162P3).

62 Kinetic analyses of vaginal infection with C. albicans in C57BL/6 mice demon

63 mounted effective immune responses following vaginal infection with Chlamydia trachomatis.

64 Vaginal infection with either HSV-1 or HSV-2 was blocked

65 ns of macaque CCR5 could prevent or suppress vaginal infection with highly virulent SIVmac251.

66 When challenged by vaginal infection with HSV-2, the DNA-immunized animals

67 Vaginal infection with the mouse pneumonitis agent of Ch

68 A Th1-type response develops following vaginal infection with the mouse pneumonitis biovar of C

69 Murine vaginal infection with the obligate intracellular bacter

70 Women with bacterial vaginosis have complex vaginal infections with many newly recognized species, i